Takeda signs US$600M AI drug discovery deal with Insilico
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to make use of AI in early-stage drug discovery throughout the Japanese pharmaceutical firm’s therapeutic areas. The corporations didn’t disclose which therapeutic areas or illness targets can be lined beneath the collaboration. The settlement provides Takeda entry to Insilico’s Pharma.AI platform, which helps organic…
